Cargando…

Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II Studies

AIM: The marked variation in bifurcation anatomy has brought about an ongoing search for stents specifically constructed for coronary bifurcations. This study aimed to analyze the angiographic restenosis prevalence and patterns and predictors of different patterns in dedicated bifurcation BiOSS® vs....

Descripción completa

Detalles Bibliográficos
Autores principales: Gil, Robert J., Bil, Jacek, Kern, Adam, Iñigo-Garcia, Luis A., Formuszewicz, Radoslaw, Dobrzycki, Slawomir, Vassilev, Dobrin, Mehran, Roxana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204374/
https://www.ncbi.nlm.nih.gov/pubmed/32411301
http://dx.doi.org/10.1155/2020/6760205
_version_ 1783530052489576448
author Gil, Robert J.
Bil, Jacek
Kern, Adam
Iñigo-Garcia, Luis A.
Formuszewicz, Radoslaw
Dobrzycki, Slawomir
Vassilev, Dobrin
Mehran, Roxana
author_facet Gil, Robert J.
Bil, Jacek
Kern, Adam
Iñigo-Garcia, Luis A.
Formuszewicz, Radoslaw
Dobrzycki, Slawomir
Vassilev, Dobrin
Mehran, Roxana
author_sort Gil, Robert J.
collection PubMed
description AIM: The marked variation in bifurcation anatomy has brought about an ongoing search for stents specifically constructed for coronary bifurcations. This study aimed to analyze the angiographic restenosis prevalence and patterns and predictors of different patterns in dedicated bifurcation BiOSS® vs. current generation drug-eluting stents implanted in coronary bifurcation lesions based on data from two clinical trials POLBOS I and II. METHODS: Dedicated bifurcation BiOSS® stents were compared with drug-eluting stents (DES) in patients with stable coronary artery disease (CAD) or nonST elevation acute coronary syndrome (NSTE-ACS) (POLBOS I: paclitaxel eluting BiOSS® Expert vs. DES; POLBOS II: sirolimus eluting BiOSS® LIM vs. DES). Provisional T-stenting was the default treatment. Morphological pattern of in-stent restenosis according to the modified Mehran classification adopted for bifurcation lesions was assessed with bifurcation dedicated quantitative coronary angiographic software (CAAS 5.11, Pie Medical Imaging BV, the Netherlands). RESULTS: In total, 445 patients (222 patients in BiOSS group and 223 patients in DES group) were included into the analysis. In BiOSS group 24 cases of angiographic restenosis (10.8%) were recorded, and in DES group—17 cases (7.6%) at 12 months follow-up (angiographic control rate at follow-up—90.3%). In the BiOSS group most frequent medina classification in restenotic cases was 0.0.1 (25%), whereas in DES—0.0.1 and 0.1.1 (23.5% each). In multivariate regression analysis proximal optimization technique was associated with the lowest chance for restenosis (OR 0.15, 95% CI 0.06–0.33), whereas diabetes on insulin was associated with the highest risk of restenosis (OR 4.21, 95% CI 1.48–11.44). CONCLUSIONS: The angiographic restenosis pattern and rate was similar between BiOSS stents and DES in coronary bifurcation lesions.
format Online
Article
Text
id pubmed-7204374
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-72043742020-05-14 Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II Studies Gil, Robert J. Bil, Jacek Kern, Adam Iñigo-Garcia, Luis A. Formuszewicz, Radoslaw Dobrzycki, Slawomir Vassilev, Dobrin Mehran, Roxana Cardiovasc Ther Research Article AIM: The marked variation in bifurcation anatomy has brought about an ongoing search for stents specifically constructed for coronary bifurcations. This study aimed to analyze the angiographic restenosis prevalence and patterns and predictors of different patterns in dedicated bifurcation BiOSS® vs. current generation drug-eluting stents implanted in coronary bifurcation lesions based on data from two clinical trials POLBOS I and II. METHODS: Dedicated bifurcation BiOSS® stents were compared with drug-eluting stents (DES) in patients with stable coronary artery disease (CAD) or nonST elevation acute coronary syndrome (NSTE-ACS) (POLBOS I: paclitaxel eluting BiOSS® Expert vs. DES; POLBOS II: sirolimus eluting BiOSS® LIM vs. DES). Provisional T-stenting was the default treatment. Morphological pattern of in-stent restenosis according to the modified Mehran classification adopted for bifurcation lesions was assessed with bifurcation dedicated quantitative coronary angiographic software (CAAS 5.11, Pie Medical Imaging BV, the Netherlands). RESULTS: In total, 445 patients (222 patients in BiOSS group and 223 patients in DES group) were included into the analysis. In BiOSS group 24 cases of angiographic restenosis (10.8%) were recorded, and in DES group—17 cases (7.6%) at 12 months follow-up (angiographic control rate at follow-up—90.3%). In the BiOSS group most frequent medina classification in restenotic cases was 0.0.1 (25%), whereas in DES—0.0.1 and 0.1.1 (23.5% each). In multivariate regression analysis proximal optimization technique was associated with the lowest chance for restenosis (OR 0.15, 95% CI 0.06–0.33), whereas diabetes on insulin was associated with the highest risk of restenosis (OR 4.21, 95% CI 1.48–11.44). CONCLUSIONS: The angiographic restenosis pattern and rate was similar between BiOSS stents and DES in coronary bifurcation lesions. Hindawi 2020-01-21 /pmc/articles/PMC7204374/ /pubmed/32411301 http://dx.doi.org/10.1155/2020/6760205 Text en Copyright © 2020 Robert J. Gil et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Gil, Robert J.
Bil, Jacek
Kern, Adam
Iñigo-Garcia, Luis A.
Formuszewicz, Radoslaw
Dobrzycki, Slawomir
Vassilev, Dobrin
Mehran, Roxana
Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II Studies
title Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II Studies
title_full Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II Studies
title_fullStr Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II Studies
title_full_unstemmed Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II Studies
title_short Angiographic Restenosis in Coronary Bifurcations Treatment with Regular Drug Eluting Stents and Dedicated Bifurcation Drug-Eluting BiOSS Stents: Analysis Based on Randomized POLBOS I and POLBOS II Studies
title_sort angiographic restenosis in coronary bifurcations treatment with regular drug eluting stents and dedicated bifurcation drug-eluting bioss stents: analysis based on randomized polbos i and polbos ii studies
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7204374/
https://www.ncbi.nlm.nih.gov/pubmed/32411301
http://dx.doi.org/10.1155/2020/6760205
work_keys_str_mv AT gilrobertj angiographicrestenosisincoronarybifurcationstreatmentwithregulardrugelutingstentsanddedicatedbifurcationdrugelutingbiossstentsanalysisbasedonrandomizedpolbosiandpolbosiistudies
AT biljacek angiographicrestenosisincoronarybifurcationstreatmentwithregulardrugelutingstentsanddedicatedbifurcationdrugelutingbiossstentsanalysisbasedonrandomizedpolbosiandpolbosiistudies
AT kernadam angiographicrestenosisincoronarybifurcationstreatmentwithregulardrugelutingstentsanddedicatedbifurcationdrugelutingbiossstentsanalysisbasedonrandomizedpolbosiandpolbosiistudies
AT inigogarcialuisa angiographicrestenosisincoronarybifurcationstreatmentwithregulardrugelutingstentsanddedicatedbifurcationdrugelutingbiossstentsanalysisbasedonrandomizedpolbosiandpolbosiistudies
AT formuszewiczradoslaw angiographicrestenosisincoronarybifurcationstreatmentwithregulardrugelutingstentsanddedicatedbifurcationdrugelutingbiossstentsanalysisbasedonrandomizedpolbosiandpolbosiistudies
AT dobrzyckislawomir angiographicrestenosisincoronarybifurcationstreatmentwithregulardrugelutingstentsanddedicatedbifurcationdrugelutingbiossstentsanalysisbasedonrandomizedpolbosiandpolbosiistudies
AT vassilevdobrin angiographicrestenosisincoronarybifurcationstreatmentwithregulardrugelutingstentsanddedicatedbifurcationdrugelutingbiossstentsanalysisbasedonrandomizedpolbosiandpolbosiistudies
AT mehranroxana angiographicrestenosisincoronarybifurcationstreatmentwithregulardrugelutingstentsanddedicatedbifurcationdrugelutingbiossstentsanalysisbasedonrandomizedpolbosiandpolbosiistudies